Kyndryl Holdings just delivered a quarter that split the tape — revenue came in ahead of estimates, the profit number didn't, and management compounded the miss with a below-consensus profit outlook and an announcement of job cuts. The stock's 9% gain over the past week now sits on shakier ground.
The Q4 results, released this morning, showed revenue of $3.769 billion against a $3.753 billion estimate — a narrow beat. But adjusted EPS came in at $0.18, missing the $0.45 consensus by $0.27, a gap wide enough to stop any post-result rally in its tracks. FY2027 revenue guidance of $14.755–$15.057 billion bracketed the $14.969 billion estimate, but the pretax profit forecast fell short of Street expectations. Then came the job cuts headline. Together, the three disclosures defined the tone of a messy print.
The positioning picture had been leaning defensive well before the results landed. Short interest climbed 17% in the past month to nearly 9.7% of the free float — around 22.2 million shares. That's not a short base at an extreme, but it's a meaningful and growing one. Borrow remains cheap at 0.43%, down 14% week-on-week, and availability is still loose, which means new shorts face little friction entering the trade. The put/call ratio told a similar defensive story: it hit 1.18 on Tuesday, roughly 1.3 standard deviations above its 20-day average of 0.86 and closing in on the 52-week high of 1.35. Options traders had already been hedging before the numbers came out.
The Street's read is mixed but tilting cautious. Recent analyst activity has been a steady stream of reinstatements and initiations at neutral-leaning ratings. Scotiabank reinstated last month with a Sector Perform and a $16.50 target; BMO Capital initiated at Market Perform with a $15.00 target. Those are measured entry points, not conviction calls. More telling is Morgan Stanley's target cut in late March — from $28 down to $13 — the kind of magnitude move that signals a structural reassessment, not just near-term caution. With the stock at $14.70 and the consensus target at $14.70, the Street is, in aggregate, offering zero upside from here. The P/E has expanded to 6.1x and the EV/EBITDA to 2.1x over the past month, but those multiples reflect a company still working through a difficult transition rather than a discount being aggressively exploited. The EV/EBIT factor score ranks in the 88th percentile — genuinely cheap on that metric — but EPS momentum scores rank in the 27th percentile on a 12-month forward basis, which tells you the market doubts the earnings recovery story.
The bull case for Kyndryl rests on its leading share in legacy IT infrastructure services, a client base heavy in financial services, and the self-help narrative of cost discipline and margin recovery. The bear case, now reinforced by today's results, points to management departures, internal control concerns previously disclosed, and a recurring question about whether the company can hit its FY28 targets. The job cuts announcement cuts both ways: cost reduction is part of the recovery playbook, but the market tends to ask what it means for execution capacity at the same time.
Peer performance provides little reassurance this week. DXC Technology, the closest correlated peer, managed a 2.9% gain on the week — a fraction of KD's pre-result rally. Cognizant slipped almost 6% over the same period, suggesting the IT services complex broadly has been under pressure. The divergence makes KD's 9% weekly move look more like a short-term squeeze than a fundamental re-rating — and the EPS miss this morning tests whether that gap can hold.
The debate now centres on whether the job cuts represent genuine earnings power recovery or a one-time cushion masking underlying revenue attrition. The FY2027 guidance range and management commentary from the earnings call are the items worth watching closely.
See the live data behind this article on ORTEX.
Open KD on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.